Although a randomized trial of AG881 versus placebo showed early clinical benefit in the treatment of treatment-naïve, nonenhancing IDH1mut gliomas (54), our data raise the possibility that D-2-HG reduction alone could have deleterious effects suggesting a role for combination treatment of IDH1mut inhibitor, AG881, and FTO inhibitor. The gene discussed is FTO; the disease is central nervous system cancer.